(lp0
S"VBI Vaccines Is An Alternative To The Agenus Inc. Failure Seeking Alpha - 18 hours ago In September last year I highlighted an opportunity to get into VBI and its RSV program on the back of Novavax's failure. A similar opportunity has arisen in the glioblastoma multiforme  space."
p1
aS"Why Fret Over Agenus Inc. Q3 Results? Motley Fool - Oct 27, 2016 And that $40.8 million loss didn't come from Agenus spending money like it's going out of style. The biotech's research and development costs did increase by 17% compared to the third quarter of 2015.Company Update : Here's Why Agenus Inc Shares Are Tumbling Today - Smarter AnalystAgenus 3Q Loss Worse Than Expected  - Investopedia"
p2
aS'Better Buy: Agenus Inc. vs. Celldex Therapeutics Motley Fool - Mar 10, 2017 Agenus Inc  and Celldex Therapeutics, Inc.  bear an uncanny resemblance to each other. Both clinical-stage biotechs are focused on developing novel cancer therapies and reported clinical-trial failures with vaccine&nbsp;...'
p3
aS'Troubling Trial Data Weighed on Agenus Inc Stock Today Motley Fool - Feb 22, 2017 Shares of Agenus Inc , a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m.Agenus Inc.  Plunges 16.3% on February 22 - Equities.comTrials Of Agenus Inc  Cancer Vaccine Ends In Absolute Failure - Market Exclusive'
p4
aS'Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Feb 6, 2017 Agenus  and Alnylam Pharmaceuticals  are both clinical-stage biotechs developing drugs that hold the potential to make a big difference for patients.'
p5
aS'Agenus announces collaboration with the National Cancer Institute to evaluate ... PR Newswire  - Jan 17, 2017 LEXINGTON, Mass., Jan. 17, 2017 /PRNewswire/ -- Agenus Inc. , an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a clinical trial collaboration with the National Cancer&nbsp;...'
p6
aS'Agenus Reports Fourth Quarter and Full Year 2016 Results PR Newswire  - Mar 9, 2017 LEXINGTON, Mass., March 9, 2017 /PRNewswire/ -- Agenus Inc. , an immuno-oncology  company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the&nbsp;...Agenus  Reports Narrower-than-Expected Q4 Loss - Yahoo FinanceAgenus Inc  Posts Earnings Results, Meets Estimates - BNB Daily '
p7
aS'Why Agenus Inc. Stock Plummeted 44.7% in October Motley Fool - Nov 7, 2016 Shares of tiny immunotherapy developer Agenus Inc.  tumbled 44.7% in October, according to data from S&amp;P Global Market Intelligence.'
p8
aS"3 Red Flags on Agenus Inc's Balance Sheet Motley Fool - Nov 23, 2016 Most of Agenus' potential is derived from a lineup of immunotherapy drug candidates. While the drugs target an alphabet soup of some of the most promising biological mechanisms for treating various cancers, the stock has encountered turbulence in ..."
p9
aS'Agenus to Report Fourth Quarter and Year End 2016 Financial Results on March 9 ... PR Newswire  - Mar 2, 2017 LEXINGTON, Mass., March 2, 2017 /PRNewswire/ -- Agenus Inc. , an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and year end 2016 financial results before&nbsp;...'
p10
a.